Quidditas Therapeutics develops a precise, recombination-based genome editing platform that can cut single- or double-stranded nucleic acids and paste sequences of any length anywhere in the genome. The company says its approach enables large, highly targeted genetic changes to replace full genes or exons, aiming to overcome efficiency, specificity and size limits of existing tools. Quidditas targets applications across gene therapy, protein bioproduction, stem cell research and regenerative medicine. Founded in 2022 by François Cherbonneau and Aurore Prunevieille, the founders bring academic and clinical biotechnology experience from institutions including Paris Saint-Louis Hospital and Massachusetts General Hospital/Harvard Medical School. The company intends to accelerate development of its platform to address complex and rare diseases and to expand opportunities in bioproduction. Its recent financing will support continued R&D and advancement of the technology toward therapeutic and industrial applications.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

May 2025